cyrilzakka/clinical-trials huggingface dataset:
Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis

Hospitalizations for severe infections associated with opioid use disorder (OUD), such as infective endocarditis (IE), have doubled in the US over the past decade and are frequently prolonged and resource-intensive. Once medically stabilized, persons with IE but without drug use typically enroll in outpatient parenteral antibiotic therapy (OPAT), while persons with IE and OUD are kept in the hospital for the duration of therapy (often 6 weeks or more) largely due to concerns of ongoing drug use. Unfortunately, hospitalization for IE with OUD infrequently includes evidence-based medication-assisted treatment (MAT) with buprenorphine or methadone to address the OUD, despite the strong evidence that MAT decreases illicit drug use and mortality. Enrolling hospitalized persons with IE due to OUD into comprehensive MAT (i.e., buprenorphine + counseling) while inpatient, and providing an intensive transitional outpatient care program supporting MAT, may support provision of outpatient IV antibiotic therapy and be cost effective. The primary aim of this pilot randomized clinical trial is to evaluate the equivalence of current practice plus buprenorphine (keeping patients with IE due to opioid use disorder in the hospital for the full duration of antibiotic treatment) compared to OPAT plus buprenorphine (discharge with outpatient treatment once medically stable).


Eligibility Criteria:
Inclusion Criteria:

* meeting OUD by DSM-V criteria
* have IE by Duke's criteria
* candidates for outpatient treatment with buprenorphine
* accepting of buprenorphine treatment
* anticipated to be discharged home after medically stabilized
* requiring ≥ 2 weeks of IV antibiotic therapy
* having ≥ 1 week of IV antibiotic therapy remaining at the time of medical readiness for discharge (as defined by the primary clinical team),
* and providing informed consent.

Exclusion Criteria:

* presence of stroke or central nervous system involvement
* clinically active embolic sequelae (e.g. pulmonary sepsis, mycotic aneurysms, splenic abscesses)
* TV treated surgically or endovascularly (AngioVac)
* presence of osteomyelitis
* fungal IE
* patients who require inpatient physical rehabilitation determined by physical or occupational therapy assessment
* current pregnancy
* current severe methamphetamine, cocaine, alcohol or benzodiazepine use disorders by DSM-V criteria
* currently enrolled in ongoing MAT for OUD
* hypersensitivity or allergy to buprenorphine
* chronic pain requiring opioids
* class III or IV heart failure
* cirrhosis
* end stage renal disease
* other significant screening laboratory/medical/psychiatric/psychosocial condition that may prevent the volunteer from safely participating in the study in the opinion of the investigator (e.g. currently suicidal)
* pending legal action that could interfere with study participation
* living more than a 45-minute drive from UK given the intense outpatient component to the intervention.
Good EULAR Response In Patients With Early Rheumatoid Arthritis

This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece

All subjects enrolled should meet the usual prescribing criteria for Etanercept as per the local product information and should be entered into the study at the investigator's discretion

Eligibility Criteria:
Inclusion Criteria:

1. signed and dated informed consent document
2. 18 years of age and older at the time of consent
3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria
4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,
5. Patients with DAS28 ≥ 3.2
6. Duration of disease symptoms ≥ 6 weeks and ≤2 years
7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.

Exclusion Criteria:

1. Contraindications according to the SmPC
2. History of or present anti-TNFa or other biologic therapy for the treatment of RA
3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC
Early Non-invasive Ventilation Outside the Intensive Care Unit

A large multicentre, randomized, controlled trial to demonstrate that non invasive ventilation given at an early stage of acute respiratory failure (ARF) outside the intensive care unit (ICU) can prevent the deterioration of ARF and the need for ICU when compared to the best available treatment usually performed in the non-ICU wards.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Age \>= 18 years
* Admission in a non-intensive-care department
* Radiological evidence of new pulmonary consolidation or atelectasis
* Peripheral Oxygen saturation less than 92% while breathing room air or PaO2/FiO2 ratio less than 300 at blood gas analysis
* Decompensated hypercapnia (pCO2 \> 45 mmHg and pH \< 7.35)
* Clinical signs of respiratory distress (dyspnoea, utilization of accessory respiratory muscles, paradox movements of thoraco-abdominal wall) in air.

Exclusion Criteria:

* Respiratory failure due to chronic obstructive pulmonary disease exacerbation, defined as PaCO2 \> 45 and pH \< 7.35 (in these patients NIV is considered to be the standard/first line treatment and we do not want to deny these patients the opportunity to receive this treatment because of randomization)
* Severe, hypercapnic ARF defined as PaCO2 \> 45 and pH \< 7.30
* Severe, hypoxic ARF defined as PaO2/FiO2 \< 200
* Need for immediate mechanical ventilation or ICU as judged by the ICU physician in charge
* Extremely poor short term prognosis (imminent death with decision for palliative treatment only)
* Invasive or non-invasive mechanical ventilation during the same hospitalization due to respiratory failure.
* Clear contraindication to NIV treatment: respiratory arrest, failure to correct positioning of a face mask, hemodynamic instability due to hypotensive shock, ongoing myocardial ischemia, arrhythmia, massive bleeding from upper gastrointestinal tract, patient uncooperative and upset, inability to protect airways, alterations of deglutition, inability to clear secretion also with external aspiration, multiple organs dysfunction, recent surgery of airways or upper gastrointestinal tract, not-drained pneumothorax, bowel obstruction, active vomit.
Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding

This pilot clinical trial aims to integrate maternal smoking cessation and breastfeeding interventions to enhance both cancer prevention behaviors. The investigators will recruit 40 daily smoking women in their early pregnancy and randomize them into the integrated intervention or control group. Main outcomes include smoking abstinence and breastfeeding rates at 6 months postpartum.

The investigators are proposing the first randomized controlled trial to integrate maternal smoking cessation and breastfeeding interventions to enhance both cancer prevention behaviors. The investigators will recruit 40 daily smoking women in their 1st or 2nd trimester of pregnancy (≤28 weeks) from local obstetric clinics, communities, and social media. They will be randomized into either the intervention (N=20) or control group (N=20). The two groups will complete the same number of sessions (6 during pregnancy and 3 postpartum), but focus on different topics. Specifically, the control group will receive instructions on general pregnancy and infant care. The intervention group will receive instructions on general pregnancy and infant care, plus an integrated multicomponent intervention that promotes both smoking cessation and breastfeeding (i.e., education and counseling, monitoring and feedback, and contingent financial incentives). Two female Certified Lactation Counselors (interventionists) will be trained to run study sessions during home visits. Interventionists will provide additional support via phone and text messaging until 6 months postpartum. Main outcomes include smoking abstinence and breastfeeding rates at 6 months postpartum within the duration of this award.

Eligibility Criteria:
Inclusion Criteria:

* Be 18 years or older
* At ≤28 weeks of pregnancy
* Daily smoking cigarettes and/or cigars in the past 7 days
* Be able to read, listen, and talk in English

Exclusion Criteria:

* Being diagnosed with cancer
* Current heavy drinking (more than 2 drinks a day)
* Current use of illicit substances
* Medical conditions contraindicating breastfeeding such as HIV infection, active tuberculosis, and breast removal
Evaluation of Subjective Ratings on a New Sound Processor and Compatible Products

Clinical study designed to collect user feedback from Cochlear Implant recipients on a new Sound Processor System


Eligibility Criteria:
Inclusion Criteria:

1. 12 months old or older
2. Implanted with a CI24RE (Freedom implant) or later implant in at least one implanted ear
3. Use of the CP810, CP920 or CP910 sound processor
4. Willingness to participate in and to comply with all requirements of the protocol

Exclusion Criteria:

1. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device
2. Additional disabilities or illnesses that would prevent participation in evaluations or compromise the integrity of the investigation or quality of data collected
3. Nucleus 22 or Nucleus 24 Implant in ear to be fitted with the investigational device
Using of SGLt2 Inhibitors in Patients With Type 2 DM

To detect the efficacy of SGLT2i in improving the metabolic parameters in patients with type 2 diabetes.

- To detect the side-effects of SGLT2i

Type 2 diabetes mellitus (T2DM) is a worldwide health problem, with a continuously increasing prevalence . Good management of blood glucose level is critical to delay progression of the underlying metabolic dysfunction and to reduce the risk of diabetic complications . Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of antidiabetic drug acting by increasing urinary glucose excretion. First approved in 2014, SGLT2i have been widely used to treat patients with type 2 diabetes They are effective in reducing blood glucose, and surprisingly have shown benefits beyond glycaemic control .

Physicians have reported improved hypertension, heart failure, chronic kidney disease, fatty liver disease and obesity However, SGLT inhibitors are not magical drugs, and their use is not free of side effects ( Reported side effects include urinary tract infections, genital infection, dehydration, and hypotension, plus the usual side effects of antidiabetic medications as hypoglycemia . The optimum practical guideline for adding SGLT2 inhibitors to treatment regimens of patients with diabetes is controversial .Many local guidelines and treatment policies exist, yet we need to develop our own local policy at Assiut University hospitals to suit our patients needs and expectations, balancing between efficacy and side effects.

Eligibility Criteria:
Inclusion Criteria:

1. Adults (≥18 years)
2. both genders ( male and female)
3. type 2 diabetic patients

Exclusion Criteria:

1. history of svere hypoglycemia
2. patients with history of weight loss
3. Patients with history of recurrent UTI
Antidiabetic Properties of Rose Hip

The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.


Eligibility Criteria:
Inclusion Criteria:

* BMI \> 30
* willingness to participate in the study
* willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

* diabetes
* previous or ongoing insulin treatment
* abnormal thyroid status
* abnormal liver status
* abnormal kidney status
* known gastrointestinal disorder
* pregnancy
* suspected allergy to ingredients of the drinks
Compare the Clinical Efficacy of Prototype Toothpastes

Clinical study to compare the clinical efficacy of toothpastes on dental plaque and gingival inflammation.


Eligibility Criteria:
Inclusion Criteria:

* Male or female volunteers 18-65 years of age.
* Good general health.
* Must sign informed consent form.
* Minimum of 20 natural uncrowned teeth (excluding third molars) must be present.
* No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.

Exclusion Criteria:

* Subject unable or unwilling to sign the informed consent form.
* Medical condition which requires pre-medication prior to dental visits/procedures.
* Moderate or advanced periodontal disease.
* 5 or more decayed untreated dental sites at screening.
* Other disease of the hard or soft oral tissues.
* Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation).
* Use of medications that currently affect salivary flow.
* Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1.
* Pregnant or nursing women.
* Participation in any other clinical study within 1 week prior to enrollment into this study.
* Use of tobacco products.
* Subjects who must receive dental treatment during the study dates.
* Current use of Antibiotics for any purpose.
* Presence of an orthodontic appliance.
* History of allergy to common dentifrice ingredients.
* History of allergy to zinc.
* Immune compromised individuals (HIV, AIDS, immuno suppressive drug therapy).
Trial of Antimicrobial Restraint in Presumed Pneumonia

The objective of this cluster-randomized crossover study is to determine the effect of delaying antimicrobial initiation until objective microbiologic data is obtained in patients with presumed ICU-acquired pneumonia without septic shock.

This study will involve 8 centers is to determine the effect of delaying antimicrobial initiation until objective microbiologic data is obtained in patients with presumed ICU-acquired pneumonia without septic shock. The study team will compare two sequential 4-month periods in each unit, one 'aggressive' antimicrobial initiation period and one 'conservative' antimicrobial initiation period.

This study will serve the following specific aims:

Specific Aim 1: To determine feasibility of a larger multicenter study of the same design as well as assess protocol adherence across multiple centers.

Specific Aim 2: Prospectively determine the all-cause, in-hospital mortality for all patients with suspected pneumonia who were treated under either an aggressive or conservative antimicrobial initiation protocol.

Specific Aim 3: Prospectively determine antimicrobial initiation rates, total days of antimicrobial administration, hospital and ICU length of stay, and ventilator-free alive days for patients treated under each protocol.

Specific Aim 4: To survey physicians that participated in the study to assess their feelings about the study including level of comfort starting antimicrobials aggressively, level of comfort withholding antimicrobials until definitive evidence of infection, perceived protocol adherence, perceived importance of the study, and willingness to participate in other studies of its kind (to be performed after closure of the clinical portion of the study).

Eligibility Criteria:
Inclusion Criteria:

* Intubated patients admitted to a surgical or trauma intensive care unit that have had an appropriate quantitative or semi-quantitative endobronchial sputum culture sent ≥48 hours into their ICU admission
* Primary pathology managed by surgical specialty
* Age ≥18 years.

Exclusion Criteria:

* Non-intubated patients.
* Intubated patients with concern for active infection that is not suspected to be pneumonia (i.e. intra-abdominal infection, skin and soft tissue infection, urinary tract infection, etc.)
* Primary disease not surgical or traumatic in nature
* Primary diagnosis of burns
* Incarcerated status
* Pregnant status or delivery during this hospitalization.
* On active immunosuppressive medications (or taking as a home medication prior to arrival)
Institut Paoli Calmettes Ovarian Cancer Database

Database of Institut Paoli-Calmettes patients diagnosed with ovarian cancer


Eligibility Criteria:
Inclusion Criteria:

* Patient with a diagnosis of ovarian cancer

Exclusion Criteria:

* Diagnosis of fallopian tube cancer
Characterization of Health Conditions of Visitors of the Montreal Museum of Fine Arts

This study evaluates the effects of arts on the Montreal Museum's clients.

Acting early in the process of weakening elders in order to keep them longer in good health and socially active is possible. During the past decade, museums have become involved in the care of patients by using art to improve their quality of life and well-being. Museums have, thus, emerged as new partners in public health. Very few programs developed by museums have focused on elders. Only one focused on elders in situation of early frailty and demonstrated that it was possible, through participatory visual art-based activities, to improve the health status of elders living at home.

Eligibility Criteria:
Inclusion Criteria:

* Being 50 years old
* Coming at Montreal Museum of Fine Arts for guided visits, arts activities, and so forth.

Exclusion Criteria

-No internet connection and electronic device like cell phone, Ipad or computer.
Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries?

Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased complications, operation duration, and blood loss. There are several pharmacological techniques for the appropriate control of intraoperative bleeding.

Objectives: To compare the safety and efficacy of oral labetalol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during endoscopic nasal surgeries.

Patients and Methods: This is a randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for endoscopic nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group L, received oral labetalol, and group M, received oral metoprolol.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status ≤ II
* Age from 21 to 50 years
* Body Mass Index (BMI) ≤ 35 kg/m2

Exclusion Criteria:

* ASA physical status \> II
* Age \< 21 years or \> 50 years
* Pregnant women
* Breastfeeding
* Bronchial asthma
* Chronic obstructive pulmonary disease
* Hypertension
* Ischemic heart disease
* Rheumatic heart disease
* Heart failure
* Heart block
* Sick sinus syndrome
* Sinus bradycardia
* Chronic hypotension
* Anemia (Hb \< 10 g/dl)
* Renal or hepatic dysfunction
* Central nervous system disease
* Bleeding diathesis
* Diabetes Mellitus
* Allergic fungal sinusitis
* Patients on beta-blockers, tricyclic antidepressants, alcohol or drug abuse, anticoagulation therapy, agents influencing the autonomic nervous system
* Patients using pacemakers
* Allergy to the study drugs
* Any contraindication of oral intake
Facilitate the Return to Work of Cancer Survivors

Cancer patients could experience physical limitations, cognitive symptoms, fatigue and pain, that could be perceived at diagnosis but may also occur during treatment, limiting the person from carrying out their activities of daily living, including work tasks. Return to work is a major goal, as it facilitates the patient's ability to deal with the disease and improve general health.

At present, there is no path aimed at supporting cancer patients in the return to work process. Because of this, the investigators want to assess the feasibility of a multidisciplinary social-health care pathway aimed at manage the difficulties that cancer patients might perceive in the return to work process.

To receive the support from the social-health care pathway, cancer survivors should go to an information desk service (called Informa Salute) located in the hospital. Here, sociodemographic and work-related data will be collected with the aim to organize the tailored social-health support to facilitate the return to work.

The social-health care pathway created includes: the local Health Authority of Reggio Emilia and the local Order of Physicians, voluntary non-profit associations, vocational and educational training bodies, social cooperatives, one labor union and one chartered accountant enterprise.

Eligibility Criteria:
Inclusion Criteria:

* adults with cancer diagnosis and employed at the time of diagnosis

Exclusion Criteria:

-
HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?

This study will help to provide better input to state health and education departments to improve the processes for CPR education. This will also help the EP council explore the opportunities to partner with other professional societies and other stake holders that have interest in this topic. Engagement of private-public partnerships for improving overall CPR education.

Schools should incorporate CPR education programs in the schools that will increase the knowledge, skills and awareness among high school children. It is important to note that, CPR training of young children, increases the self confidence, esteem, responsibility and contribution to their community.Moreover, it is clearly shown that, high school children has the required physical strength, maturity and positive attitude towards performing CPR in family members, friends and strangers in the community. Although some studies suggest benefit of periodic retraining, few studies have attempted to collectively identify contributing factors to comprehension.It is an attempt to identify national distribution of training efforts and factors implicated in comprehension among high school students.

Eligibility Criteria:
Inclusion Criteria:

* High school students completing voluntary survey

Exclusion Criteria:

* Inability to give consent
* Inability to complete survey